| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.aartidrugs.com | |
| Market Cap | 3,889.20 Cr. | |
| Enterprise Value(EV) | 4,427.54 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 22.14 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 18.97 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 29.26 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 111.92 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 3.75 | Calculated using Price: 420.00 |
| Dividend Yield | 0.60 | Period Ending 2021-03 |
| No. of Shares Subscribed | 9.26 Cr. | 92,600,000 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Aarti Drugs (ADL), incorporated in 1984, is engaged in the business of manufacturing generic bulk actives, advanced intermediates and specialty chemicals. The company is part of $265 million Aarti Group of Industries. ADL manufactures drugs in therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, anti-cholinergic, sedatives, anti-depressant, anti-diarrhea and anti-inflammatory. The company’s manufacturing facilities are located at Tarapur and Sarigam. The drug major has received ISO 9001:2000 certifications for quality management. Products API- ADL manufactures active pharmaceuticals ingredients (API) and steroids. Under API, it manufactures products such as aceclofenac, clopidogrel bisulphate, ketoconazole, metformin HCl, hydroxyzine pomoate, ketoconazole, irbesartan and many more. The company manufactures steroids such as hydrocortisone sodium succinate sterile, hydrocortisone acetate, hydrocortisone and hemisuccinate. Pharma Intermediates- The company manufactures pharma intermediates for irbesartan, Zolpidem Tartrate, Tamsulosin HCL, Leflunomide and Levocetirizine Speciality Chemicals- Under this, the company manufactures products such as benzene sulphonyl chloride, benzene sulphonamide, diphenyl sulphone, N-ethyl toluene sulphonamide, ethyl toluene sulphonate, para chloro benzene sulphonamide, benzene sulfonyl hydrazide and many more. The company’s R&D centre at Turbhe near Mumbai, focuses on developing new value added molecules. This facility is recognised by Department of Science and Industrial Research and Government of India. The company also undertakes contract manufacturing for its customers. ADL's products are exported to over 85 countries across the globe. It has received Export House Status recognition of from Government of India. The company has clientele namely Sanofi-Aventis, Merck, Teva , Searle, Pfizer, Bayer and Clariant to name a few. New Development Aarti Drugs' R&D programs are currently focused on new products amongest non-steroidal NSAID compounds, antiparasitic, calciun antagonist, antianginal, antidiabetics, antdepressant and many more. The company has also planned to work on speciality chemicals and agro chemicals. |
||
Company Profile
Aarti Drugs (ADL), incorporated in 1984, is engaged in the business of manufacturing generic bulk actives, advanced intermediates and specialty chemicals. The company is part of $265 million Aarti Group of Industries.
ADL manufactures drugs in therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, anti-cholinergic, sedatives, anti-depressant, anti-diarrhea and anti-inflammatory. The company’s manufacturing facilities are located at Tarapur and Sarigam. The drug major has received ISO 9001:2000 certifications for quality management.
Products
API- ADL manufactures active pharmaceuticals ingredients (API) and steroids. Under API, it manufactures products such as aceclofenac, clopidogrel bisulphate, ketoconazole, metformin HCl, hydroxyzine pomoate, ketoconazole, irbesartan and many more. The company manufactures steroids such as hydrocortisone sodium succinate sterile, hydrocortisone acetate, hydrocortisone and hemisuccinate.
Pharma Intermediates- The company manufactures pharma intermediates for irbesartan, Zolpidem Tartrate, Tamsulosin HCL, Leflunomide and Levocetirizine
Speciality Chemicals- Under this, the company manufactures products such as benzene sulphonyl chloride, benzene sulphonamide, diphenyl sulphone, N-ethyl toluene sulphonamide, ethyl toluene sulphonate, para chloro benzene sulphonamide, benzene sulfonyl hydrazide and many more.
The company’s R&D centre at Turbhe near Mumbai, focuses on developing new value added molecules. This facility is recognised by Department of Science and Industrial Research and Government of India.
The company also undertakes contract manufacturing for its customers.
ADL's products are exported to over 85 countries across the globe. It has received Export House Status recognition of from Government of India. The company has clientele namely Sanofi-Aventis, Merck, Teva , Searle, Pfizer, Bayer and Clariant to name a few.
New Development
Aarti Drugs' R&D programs are currently focused on new products amongest non-steroidal NSAID compounds, antiparasitic, calciun antagonist, antianginal, antidiabetics, antdepressant and many more. The company has also planned to work on speciality chemicals and agro chemicals.
| 1 Day |
|
+1.45% |
| 1 Week |
|
-1.07% |
| 1 Month |
|
-13.12% |
| 3 Month |
|
-15.89% |
| 6 Month |
|
-21.01% |
| 1 Year |
|
-44.48% |
| 2 Year |
|
+110.79% |
| 5 Year |
|
+220.0% |
| 10 Year |
|
+3081.82% |
| 9 years | 2010-03 | 2011-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 21.09 | 15.18 | 32.78 | 20.65 | 21.60 | 19.24 | 17.97 | 23.65 | 35.81 | |
| Return on Capital Employed (%) | 20.30 | 13.12 | 23.93 | 18.33 | 18.50 | 17.31 | 17.01 | 21.39 | 34.52 | |
| Return on Assets (%) | 6.92 | 4.99 | 10.13 | 6.53 | 7.13 | 6.38 | 6.31 | 9.33 | 16.78 |
| Particulars | 9 years | 2011-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 163 | 308 | 357 | 400 | 455 | 543 | 652 | 913 | 1,036 | |
| Non Curr. Liab. | 290 | 211 | 244 | 297 | 312 | 321 | 301 | 257 | 232 | |
| Curr. Liab. | 70 | 483 | 501 | 494 | 622 | 591 | 623 | 595 | 940 | |
| Minority Int. | 0 | 0 | ||||||||
| Equity & Liab. | 523 | 1,002 | 1,102 | 1,191 | 1,389 | 1,455 | 1,577 | 1,766 | 2,208 | |
| Non Curr. Assets | 264 | 476 | 537 | 620 | 653 | 671 | 673 | 709 | 815 | |
| Curr. Assets | 260 | 526 | 565 | 571 | 737 | 784 | 904 | 1,057 | 1,393 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 523 | 1,002 | 1,102 | 1,191 | 1,389 | 1,455 | 1,577 | 1,766 | 2,208 |
| Particulars | 10 years | 2010-03 Rs. Cr. | 2011-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 479 | 501 | 1,097 | 1,140 | 1,195 | 1,244 | 1,561 | 1,806 | 2,155 | 2,489 | |
| Other Income | 1 | 0 | 1 | 4 | 1 | 2 | 1 | 5 | 11 | ||
| Total Income | 479 | 501 | 1,098 | 1,140 | 1,199 | 1,245 | 1,563 | 1,808 | 2,159 | 2,500 | |
| Total Expenditure | -396 | -432 | -925 | -960 | -1,005 | -1,042 | -1,350 | -1,541 | -1,714 | -2,159 | |
| PBIDT | 83 | 69 | 173 | 180 | 194 | 203 | 213 | 267 | 445 | 341 | |
| Interest | -19 | -17 | -42 | -48 | -40 | -38 | -44 | -37 | -26 | -21 | |
| Depreciation | -17 | -19 | -31 | -37 | -38 | -40 | -43 | -49 | -50 | -50 | |
| Taxation | -19 | -10 | -22 | -27 | -34 | -42 | -41 | -44 | -89 | -65 | |
| Exceptional Items | 4 | 4 | 0 | ||||||||
| PAT | 28 | 24 | 77 | 69 | 82 | 82 | 90 | 141 | 280 | 205 | |
| Minority Interest | 0 | 0 | 0 | ||||||||
| Share Associate | 0 | 0 | |||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 28 | 24 | 77 | 69 | 82 | 82 | 90 | 141 | 280 | 205 | |
| Adjusted EPS | 3 | 2 | 8 | 7 | 9 | 9 | 10 | 15 | 30 | 22 |
| Particulars | 8 years | 2011-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 21 | 105 | 133 | 175 | 70 | 143 | 251 | 155 | |
| Cash Fr. Inv. | -76 | -107 | -99 | -107 | -74 | -62 | -33 | -72 | |
| Cash Fr. Finan. | 53 | 1 | -33 | -68 | 4 | -80 | -215 | -81 | |
| Net Change | -3 | -1 | 1 | 0 | 0 | 1 | 2 | 2 | |
| Cash & Cash Eqvt | 5 | 4 | 5 | 3 | 3 | 5 | 7 | 9 |
|
Mon, 16 May 2022
Announcement under Regulation 30 (LODR)-Earnings Call Transcript Please find attached herewith transcript of Q4 FY22 Earning Conference call. |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Fri, 13 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.
Date: 13/05/2022 |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Tue, 10 May 2022
Recording Of Conference Call In continuation to our letter dated May 5 2022 regarding intimation of Investors/ Analyst conference call on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2022 we would like to inform you that the audio recording of the said call has been uploaded on the Companys website. This can be accessed via the following link. Link: https://www.aartidrugs.co.in/concalls-transcript/ |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Fri, 20 May 2022 |
Opening at Low
|
Close Within 52 Week Low Zone
|
High Decrease 1 Month
|
High Decrease 3 Months
|
High Decrease 6 Months
|
Equities
M.F.
Sectors